Metformina – nowe spojrzenie na stary lek

• Authors: Zdrojewicz Zygmunt , Belowska-Bień Kinga
• Languages of publication: PL

Keywords

PL

metformina; stany przedcukrzycowe; nowotwór

• Publisher: Stowarzyszenie Przyjaciół Medycyny Rodzinnej i Lekarzy Rodzinnych
• Journal: Family Medicine & Primary Care Review
• Year: 2013
• Issue: 1
• Pages: 43-45

Contributors

author

Zdrojewicz Zygmunt

author

Belowska-Bień Kinga

References

• Bailey CJ , Day C. Traditional plant medicines as treatments for diabetes. Diabetes Care 1989; 12: 553–556.
• Bailey CJ , Day C. Metformin: its botanical background. Pract Diab Inter 2004; 21(3): 115–174.
• Werner E, Bell J. The preparation of methylguanidine, and of ß-dimethylguanidine by the interaction of dicyanodiamide, and methylammonium and dimethylammonium chlorides respectively. J Chem Soc Transactions 1922; 121: 1790–1795.
• Werner E, Bell J. Über Biguanide. II . Die Blutzuckersenkende Wirkung der Biguanides. Ber Deuts Chem Gesellschaft 1929;62: 1398–1405.
• Garcia EY . Fluamine, a new synthetic analgesic and antiflu drug. J Philippine Med Assoc 1950; 26: 287–293.
• Stupniewski J, Chruściel T. N-dimethyl-di-guanide and its biological properties. Arch Immunol Ther Exp 1954; 2: 1–15.
• Pollack MN . Insulin, insulin-like growth factors, insulin resistance, and neoplasia. Am J Clin Nutr 2007; 86(3): 820–822.
• Mor V, Unnikrishnan MK. 5’-adenosine monophosphate-activated protein kinase and the metabolic syndrome. Endocr Metab Immune Disord Drug Targets 2011; 1(11), 3: 206–216.
• Traczyk S, i wsp. Fizjologia człowieka z elementami fizjologii stosowanej i klinicznej. Warszawa: Wydawnictwo Lekarskie PZWL ; 2003: 381–383.
• Boden G, Shulman GI . Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002; 32(3): 14–23.
• Abdul-Ghani MA . Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 2006; 29(5): 1130–1139.
• Nathan DM , Davidson MB. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007; 30(3): 753–759.
• Bandurska-Stankiewicz E, i wsp. Stanowisko Polskiego Towarzystwa Badań nad Otyłością w kwestii stosowania metforminy u osób otyłych w stanach przedcukrzycowych. Endokrynol Otyłość Zab Przem Materii 2011; 7(2): 151–154.
• Knowler WC . Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 7(346),6: 393–403.
• Goodwin PJ, Stambolic V. Obesity and insulin resistance in breast cancer – chemoprevention strategies with a focus on metformin.Breast 2011; 20(3): 31–35.
• Ibarra-Drendall C, Dietze EC , Seewaldt VL. Metabolic syndrome and breast cancer risk: is there a role for metformin? Curr Breast Cancer Rep 2011; 3(3): 142–150.
• Vakana E, Altman JK, Glaser H, et al. Antileukemic effects of AM PK activators on BCR -ABL expressing cells. Blood 2011; 118,24: 6399–6402.
• Zhang ZJ. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care 2011; 34(10): 2323–2328.
• Bo S, Ciccone G, Rosato R, et al. Cancer mortality reduction and metformin. A retrospective cohort study in type 2 diabetic patients. Diabetes Obes Metab 2011; (3): 1463.
• Bodmer M, Becker C, Meier C, et al. Use of metformin and the risk of ovarian cancer: a case-control analysis. Gynecol Oncol 2011; 123(2): 200–204.
• Rattan R, Graham RP, Maguire JL , et al. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia 2011; 13(5): 483–491.
• Legro RS , Barnhart HX, Schlaff WD . Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007; 356(6): 551–66.
• De Leo V, Musacchio MC , Piomboni P, et al. The administration of metformin during pregnancy reduces polycystic ovary syndrome related gestational complications. Eur J Obstet Gynecol Reprod Biol 2011; 157(1): 63–66.
• Melemedjian OK, et al. Targeting adenosine monophosphate-activated protein kinase (AM PK) in preclinical models reveals a potential mechanism for the treatment of neuropathic pain. Mol Pain 2011; 21(7): 70.
• Jeyabalan J, Shah M, Viollet B, et al. AM P-activated protein kinase pathway and bone metabolism. J Endocrinol 2011; 212(3):277–290.